Author pages are created from data sourced from our academic publisher partnerships and public sources.
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.
OBJECTIVE It is well established that the risk of developing type 2 diabetes is closely linked to the presence and duration of overweight and obesity. A reduction in the incidence of type 2 diabetes… Expand
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
CONTEXT Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. OBJECTIVE To test the… Expand
Role of Orlistat in the Treatment of Obese Patients With Type 2 Diabetes: A 1-year randomized double-blind study
OBJECTIVE Obesity is an important risk factor for type 2 diabetes. Weight loss in patients with type 2 diabetes is associated with improved glycemic control and reduced cardiovascular disease risk… Expand
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Compared to best-in-class GLP-1 mono-agonists, unimolecular co-agonists of GLP-1 and GIP with optimized pharmacokinetics enhance glycemic and metabolic benefits in mammals. “Twincretins”: Two Is… Expand
Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
CONTEXT The prevalence of overweight and obesity in children and adolescents is increasing rapidly. In this population, behavioral therapy alone has had limited success in providing meaningful,… Expand
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
- J. Hill, J. Hauptman, +5 authors L. Aronne
- The American journal of clinical nutrition
- 1 June 1999
BACKGROUND Long-term maintenance of weight loss remains a therapeutic challenge in obesity treatment. OBJECTIVE This multicenter, double-blind, placebo-controlled study was designed to test the… Expand
Orlistat in the long-term treatment of obesity in primary care settings.
- J. Hauptman, C. Lucas, M. Boldrin, H. Collins, K. Segal
- Archives of family medicine
- 1 February 2000
OBJECTIVE To evaluate the long-term efficacy and tolerability within primary care settings of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity. DESIGN Randomized,… Expand
Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.
BACKGROUND Orlistat is a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, promotes weight loss, and may reduce the risk of developing impaired glucose… Expand
Retrospective population‐based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers
- J. Zhi, A. T. Melia, +4 authors I. Patel
- Medicine, Chemistry
- Clinical pharmacology and therapeutics
- 1 July 1994
Orlistat, an inhibitor of gastrointestinal lipases, limits the absorption of ingested fat and could become a potential treatment for obesity. This analysis was performed to elucidate the relationship… Expand
Obesity: Low-Dose Orlistat Effects on Body Weight of Mildly to Moderately Overweight Individuals: A 16 Week, Double-Blind, Placebo-Controlled Trial
Background: Lifestyle measures are considered the first line of therapy for treating overweight individuals, but many are unable to achieve a meaningful weight loss. Objective: To determine the… Expand